MA
DNTH icon

MYDA Advisors’s Dianthus Therapeutics DNTH Stock Holding History

MYDA Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,750
Closed -$85K – 93
2022
Q3 		$85K Hold
3,750
– – 0.04% 141
2022
Q2 		$72K Buy
+3,750
New +$92.7K 0.02% 169
2020
Q1 		– Sell
-1,375
Closed -$334K – 132
2019
Q4 		$334K Buy
+1,375
New +$257K 0.15% 85

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MYDA Advisors's DNTH Position: Q4 2022 in Review

MYDA Advisors sold out of Dianthus Therapeutics (DNTH) in Q4 2022, closing a stake of 3,750 shares — an estimated $85K sold.

MYDA Advisors first reported a position in DNTH in Q4 2019 and held it in 3 quarters. The position peaked at $334K in Q4 2019. 53 funds tracked by Wall St. Rank hold DNTH as of Q4 2022.

  • MYDA Advisors reported no remaining Dianthus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • MYDA Advisors sold 3,750 Dianthus Therapeutics shares in Q4 2022, an estimated $85K.
  • MYDA Advisors first reported a position in Dianthus Therapeutics in Q4 2019 and held it in 3 quarters.
  • MYDA Advisors's Dianthus Therapeutics position peaked at $334K in Q4 2019.
  • 53 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2022.

Based on MYDA Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.